Designed For Prolonged Exposure1,2
ONIVYDE® (irinotecan liposome injection) is a novel encapsulation of irinotecan in a long-circulating liposome
- The half-life (T1/2) of total irinotecan following administration of ONIVYDE 70 mg/m2 is 25.8 hours
- 95% of irinotecan remains liposome encapsulated for up to 169.5 hours following administration
- T1/2 of total SN-38 (an active form of irinotecan) following administration of ONIVYDE is 67.8 hours
- In mice bearing human tumor xenografts, ONIVYDE achieved similar intratumoral exposure of SN-38 at a 5-fold lower dose than irinotecan HCl
HCl=hydrochloride; PEG-DSPE=polyethylene glycol-distearoylphosphatidylethanolamine.